1. Home
  2. MRVI vs GBLI Comparison

MRVI vs GBLI Comparison

Compare MRVI & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • GBLI
  • Stock Information
  • Founded
  • MRVI 2014
  • GBLI 2016
  • Country
  • MRVI United States
  • GBLI United States
  • Employees
  • MRVI N/A
  • GBLI N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • GBLI Property-Casualty Insurers
  • Sector
  • MRVI Health Care
  • GBLI Finance
  • Exchange
  • MRVI Nasdaq
  • GBLI Nasdaq
  • Market Cap
  • MRVI 376.2M
  • GBLI 428.9M
  • IPO Year
  • MRVI 2020
  • GBLI 2003
  • Fundamental
  • Price
  • MRVI $3.14
  • GBLI $29.30
  • Analyst Decision
  • MRVI Hold
  • GBLI
  • Analyst Count
  • MRVI 9
  • GBLI 0
  • Target Price
  • MRVI $4.54
  • GBLI N/A
  • AVG Volume (30 Days)
  • MRVI 1.7M
  • GBLI 2.3K
  • Earning Date
  • MRVI 11-06-2025
  • GBLI 10-30-2025
  • Dividend Yield
  • MRVI N/A
  • GBLI 4.79%
  • EPS Growth
  • MRVI N/A
  • GBLI N/A
  • EPS
  • MRVI N/A
  • GBLI 1.94
  • Revenue
  • MRVI $219,830,000.00
  • GBLI $441,717,000.00
  • Revenue This Year
  • MRVI N/A
  • GBLI $5.48
  • Revenue Next Year
  • MRVI $7.27
  • GBLI $7.91
  • P/E Ratio
  • MRVI N/A
  • GBLI $15.11
  • Revenue Growth
  • MRVI N/A
  • GBLI N/A
  • 52 Week Low
  • MRVI $1.67
  • GBLI $26.94
  • 52 Week High
  • MRVI $8.29
  • GBLI $37.00
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 48.93
  • GBLI 50.94
  • Support Level
  • MRVI $3.01
  • GBLI $28.55
  • Resistance Level
  • MRVI $3.55
  • GBLI $29.31
  • Average True Range (ATR)
  • MRVI 0.19
  • GBLI 0.30
  • MACD
  • MRVI -0.06
  • GBLI 0.04
  • Stochastic Oscillator
  • MRVI 20.31
  • GBLI 61.94

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.

Share on Social Networks: